Short-Acting Insulin

548 Words2 Pages

Short-acting regular insulin
Native or regular insulin molecules associate as hexamers in aqueous solution at a neutral pH and ¬¬¬___ aggregation slows absorption following subcutaneous injection. Regular insulin should be injected 30-45 minutes before a meal. Regular insulin also may be given intravenously or intramuscularly.

Short-acting insulin analogs
The development of short-acting insulin analogs that retain a monomeric or dimeric configuration is a major advance in insulin therapy. These analogs are absorbed more rapidly from subcutaneous sites than regular insulin. Consequently, there is a more rapid inscrease in plasma insulin concentration and an earlier response. Insulin analogs should be injected ≤15 minutes before a meal.

Insulin lispro (HUMALOG) is identical to human insulin except at positions B28 and B29, where the sequence of …show more content…

Neutral protamine hagedorn (NPH; insulin isophane) is a suspension of native insulin complexed with zinc and protamine in a phosphate buffer. This produces a cloudy or whitish solution in contrast to the clear appearance of other insulin solutions. Because of this formulation, the insulin dissolves more gradually when injected subcutaneously and thus its duration of action is prolonged. NPH insulin is usually given either once a day (at bedtime) or twice a day in combination with short-acting insulin. In patients with type 2 diabetes, long-acting insulin is often given at bedtime to help normalise fasting blood glucose. It should be noted that the use of long-acting basal insulin alone will not control postprandial glucose elevation in insulin-deficient type 1 or 2 diabetes.

Insulin glargine (LANTUS) is a long-acting analog of human insulin that is produced following two alterations of human insulin. Two arginine residues are added to the C terminus of the B chain, and an asparagine molecule in position 21 on the A chain is replaced with glycine. Insulin glargine is a clear solution with a pH of

More about Short-Acting Insulin

Open Document